Inventor · disambiguated record
Carlos Garcia-Echeverria
Also filed as: GARCIA-ECHEVERRIA CARLOS
13 granted patents·55 pending applications·389 citations·filing 1997–2019
93Inventor score
Files withGARCIA-ECHEVERRIA CARLOS19NOVARTIS AG19CHENE PATRICK5BRACHMANN SASKIA MARIA2BUONAMICI SILVIA2
Top patents by PatentIndex Score
68 records- 0197US7667039B21,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitorsNOVARTIS AG·Filed 2006·Granted Feb 23, 2010·90 cites·2 claims
- 0292US7893074B22, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disordersNOVARTIS AG·Filed 2004·Granted Feb 22, 2011·55 cites·9 claims
- 0390US8431592B21,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2011·Granted Apr 30, 2013·13 cites·5 claims
- 0490US7994170B21,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitorsNOVARTIS AG·Filed 2009·Granted Aug 9, 2011·12 cites·5 claims
- 0590US7083983B2Inhibitors of the interaction between P53 and MDM2CANCER RES CAMPAIGN TECH·Filed 1997·Granted Aug 1, 2006·108 cites·15 claims
- 0689US8263590B2Pyrimidine derivativesGARCIA-ECHEVERRIA CARLOS·Filed 2011·Granted Sep 11, 2012·19 cites·13 claims
- 0788US8629141B2Spiro-oxindole MDM2 antagonistsWANG SHAOMENG·Filed 2012·Granted Jan 14, 2014·14 cites·19 claims
- 0887US7326699B24-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivativesNOVARTIS AG·Filed 2002·Granted Feb 5, 2008·28 cites·9 claims
- 0986US7964592B22,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disordersNOVARTIS AG·Filed 2004·Granted Jun 21, 2011·29 cites·17 claims
- 1083US9370508B2Imidazoquinolines as dual lipid kinase and mTOR inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2008·Granted Jun 21, 2016·13 cites·1 claims
- 1175US7998972B21H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseasesNOVARTIS AG·Filed 2003·Granted Aug 16, 2011·8 cites·9 claims
- 1268US2011236379A1Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitorGARCIA-ECHEVERRIA CARLOS·Filed 2009·Application pending·0 cites
- 1362US2014328834A1Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitorNOVARTIS AG·Filed 2014·Application pending·0 cites
- 1462US2011195966A1Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitorNOVARTIS AG·Filed 2009·Application pending·0 cites
- 1558US2010210650A1Isoxazole compound for the treatment of cancerNOVARTIS AG·Filed 2008·Application pending·0 cites
- 1658US2011033453A1Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family membersGARCIA-ECHEVERRIA CARLOS·Filed 2009·Application pending·0 cites
- 1758US2011020338A15Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic ProcessesGARCIA-ECHEVERRIA CARLOS·Filed 2009·Application pending·0 cites
- 1857US2020022967A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1956US9084781B2MEK mutations conferring resistance to MEK inhibitorsGARRAWAY LEVI A·Filed 2009·Granted Jul 21, 2015·0 cites·13 claims
- 2056US2011230444A1Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitorNOVARTIS AG·Filed 2009·Application pending·0 cites
- 2156US2012207751A1Imidazoquinolines as lipid kinase inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2012·Application pending·0 cites
- 2256US2011105521A1Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathwayNOVARTIS AG·Filed 2009·Application pending·0 cites
- 2355US2012219550A1Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitorGARCIA-ECHEVERRIA CARLOS·Filed 2012·Application pending·0 cites
- 2455US2018325883A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2554US9241939B2Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathwayGARCIA-ECHEVERRIA CARLOS·Filed 2014·Granted Jan 26, 2016·0 cites·4 claims
- 2654US2010075337A1Method of identification of cells that show sensitivity to modulation of signalingh mediated by fibroblast growth factor receptor or a variant thereofGRAUS PORTA DIANA·Filed 2008·Application pending·0 cites
- 2753US2012315648A1Method of identification of cells that show sensitivity to modulation of signaling mediated by a fibroblast growth factor receptor or a variant thereofGRAUS PORTA DIANA·Filed 2012·Application pending·0 cites
- 2852US2006205673A12-Amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivativesFURET PASCAL·Filed 2006·Application pending·0 cites
- 2952US2015209362A1Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitorGARCIA-ECHEVERRIA CARLOS·Filed 2015·Application pending·0 cites
- 3052US2011230499A1Hsp90 inhibitors for therapeutic treatmentNOVARTIS AG·Filed 2009·Application pending·0 cites
- 3152US2018133226A1Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitorNOVARTIS AG·Filed 2018·Application pending·0 cites
- 3251US2018085362A1Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitorNOVARTIS AG·Filed 2017·Application pending·0 cites
- 3351US2014161722A1Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family membersGARCIA-ECHEVERRIA CARLOS·Filed 2014·Application pending·0 cites
- 3451US2014288075A1Isoxazole compound for the treatment of cancerCHENE PATRICK·Filed 2014·Application pending·0 cites
- 3549US2005137137A1Inhibitors of the Interaction between p53 and MDM2Filed 2004·Application pending·0 cites
- 3649US2015346204A1MEK Mutations Conferring Resistance to MEK InhibitorsGARRAWAY LEVI A·Filed 2015·Application pending·0 cites
- 3748US2013209461A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersBRACHMANN SASKIA MARIA·Filed 2011·Application pending·0 cites
- 3848US2012282252A15Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic ProcessesGARCIA-ECHEVERRIA CARLOS·Filed 2012·Application pending·0 cites
- 3948US2008262021A11H-Imidazoquinoline Derivatives as Prote In Kinase InhibitorsNOVARTIS AG·Filed 2004·Application pending·0 cites
- 4047US2016346292A1Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitorGARCIA-ECHEVERRIA CARLOS·Filed 2016·Application pending·0 cites
- 4147US2012214813A1Isoxazole compound for the treatment of cancerCHENE PATRICK·Filed 2012·Application pending·0 cites
- 4247US2010196365A1Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family membersNOVARTIS AG·Filed 2008·Application pending·0 cites
- 4347US2005215564A1Methods and compositions for treating hyperproliferative conditionsSTILES CHARLES D·Filed 2002·Application pending·0 cites
- 4447US2014242088A1Hsp90 inhibitor combinationsGARCIA-ECHEVERRIA CARLOS·Filed 2014·Application pending·0 cites
- 4547US2014057904A1Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathwayGARCIA-ECHEVERRIA CARLOS·Filed 2013·Application pending·0 cites
- 4646US2016220576A1Isoxazole compound for the treatment of cancerCHENE PATRICK·Filed 2016·Application pending·0 cites
- 4746US2012083496A1Isoxazole compound for the treatment of cancerCHENE PATRICK·Filed 2011·Application pending·0 cites
- 4846US2015025074A1Methods and compositions for treating solid tumors and other malignanciesBUONAMICI SILVIA·Filed 2014·Application pending·0 cites
- 4945US2006058324A14-Amino-5-phenyl-7-cyclohexyl-pyrrolo 2,3-d pyrimidine derivativesCAPRARO HANS-GEORG·Filed 2003·Application pending·0 cites
- 5045US2011098280A12,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disordersNOVARTIS AG·Filed 2011·Application pending·0 cites
Showing the top 50 of 68 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →